Absci is a biotechnology company that applies generative AI and wet-lab automation to design and validate biologic drug candidates, with a particular focus on antibodies and other protein therapeutics. Its platform aims to compress early discovery timelines by iterating designs computationally and then testing them in integrated laboratory workflows. The company partners with pharmaceutical and biotech firms rather than selling finished medicines directly to patients.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 1.2 | — | -26.4 | — |
| Q2 2025 | 0.6 | — | -30.6 | — |
| Q3 2025 | 0.4 | — | -28.7 | — |
| Q4 2025 | 0.7 | — | -29.6 | — |
| Q1 2026 | 0.2 | -81.8% | -29.6 | — |
| Q2 2026 | 0.3 | -46.4% | -33.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Amalgamated Financial Corp. (AMAL), Arhaus, Inc. (ARHS), Burke & Herbert Financial Services Corp. (BHRB), Hemab Therapeutics Holdings, Inc. (COAG), Atlanticus Holdings Corporation (ATLC), Bandwidth Inc. (BAND)